CereVasc is developing the eShunt® System, a percutaneously implanted, minimally invasive device for treating communicating hydrocephalus. The system provides a reliable cerebrospinal fluid drainage pathway that aims to reduce shunt malfunction, infection, and over‑drainage, thereby lowering revision surgeries, hospital stays, and overall treatment costs for neurosurgeons and hospitals.
Funding
$70M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Communicating hydrocephalus, caused by impaired absorption of cerebrospinal fluid, leads to elevated intracranial pressure and severe neurological symptoms. The standard treatment—ventriculo‑peritoneal shunt placement—is an invasive surgery with high failure rates (over 40% within two years) and costly revision procedures.
Solution
CereVasc is developing the eShunt® System, a minimally invasive device intended to treat communicating hydrocephalus without the extensive surgery required for traditional shunts. The system is designed to be implanted percutaneously, reducing operative time, anesthesia exposure, and hospital stay. By providing a more reliable CSF drainage pathway, the eShunt aims to lower the incidence of shunt malfunction, infection, and over‑drainage that drive frequent revisions. Clinical programs such as the ETCHES and STRIDE studies are evaluating safety and efficacy in both adult and pediatric populations. If successful, the eShunt could improve patient outcomes while decreasing overall treatment costs for this prevalent neurological condition.
Target Audience
Primary customers are neurosurgeons and hospitals that treat hydrocephalus patients, as well as healthcare systems seeking less invasive, cost‑effective solutions for cerebrospinal fluid management.
Features
- Percutaneous, minimally invasive implantation technique that avoids full craniotomy and general anesthesia
- Integrated CSF drainage mechanism engineered to reduce obstruction, infection, and over‑drainage risks
- Designed for both adult and pediatric patients with communicating hydrocephalus, including normal‑pressure hydrocephalus
- Ongoing multi‑center clinical trials (e.g., ETCHES, STRIDE) assessing safety, efficacy, and long‑term performance
- Potential for reduced hospital stay and lower procedural costs compared with conventional ventriculo‑peritoneal shunts